钟志远
时间:2019-12-26


个人简介:钟志远,苏州大学药学院院长,放射医学与辐射防护国家重点实验室放药中心主任,国家杰出青年基金获得者,国家“万人计划”创新领军人才,国家百千万工程人才,美国医学与生物工程院会士,药剂学TOP期刊Journal of Controlled ReleaseIF 11.467)副主编,药理学/毒理学全球高被引科学家。曾任Biomacromolecules副主编和苏州工业园区生物产业发展有限公司(苏州生物医药产业园)副总裁。研究领域涉及药物控制释放(包括化药、蛋白和核酸药物、核药等)、肿瘤靶向治疗和免疫治疗。在国际主流期刊发表论文300多篇,论文共被引用22000多次,H-因子77。授权50多项国家和国际发明专利(转让12项)。担任Mater. Today, Acta Pharmaceutica Sinica B, Biomacromolecules, Nanotechnology, PLoS One, Mater. Today Chem., J. Gene Med.8本国际期刊及《药学学报》编委。担任新型高分子材料与控制释放系列高水平国际学术会议主席。荣获美国化学会的“生物大分子/大分子青年研究者奖”、德国洪堡基金会“贝塞尔研究奖” 、日本控制释放学会颁发的“亚洲药物释放系统突破技术奖”等国际奖励。享受国务院政府特殊津贴。

  

代表性论文:

1.  J.J. Wei, D. Wu, S.S. Zhao, Y. Shao, Y.F. Xia, F.H. Meng*, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, and Z.Y. Zhong*, Immunotherapy of Malignant Glioma by Non-Invasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant, Adv. Sci. 2022, 202103689.

2. H. Zheng, B.B. Guo, X.Y. Qiu, Y.F. Xia, Y. Qu, L. Cheng,* F.H. Meng*, Z.Y. Zhong*, Polymersome-Mediated Cytosolic Delivery of Cyclic Dinucleotide STING Agonist Enhances Tumor Immunotherapy, Bioactive Mater. 2022, 16, 1-11.

3. Y. Zheng*, Z.Y. Zhong*, Roadmap to next-generation cancer vaccines, J. Control. Release. 2022, 347, 308-313.

4. J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy, J. Control. Release. 2022, 347, 68-77.

5. H.H. Fang, Y.J. Sha, L. Yang, J.J. Jiang, L.C. Yin, J.Y. Li, B. Li, B. Klumperman, Z.Y. Zhong*, and F.H. Meng*, Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy, ACS Appl. Mater. Interfaces. 2022, 14, 8824-8837.

6. Z. Wang, S.S. Zhao, F.H. Meng*, J.D. Yuan, andZ.Y. Zhong*,Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: A comparative study of molecular inhibitors and siRNA therapeutics, Acta Biomaterialia. 2022, 138, 443-452.

7. X.Y.Qiu, Y.Qu, B.B.Guo, H.Zheng, F.H. Meng*, andZ.Y. Zhong*,Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer, J. Control. Release. 2022, 341, 498-510.

8. Y.F. Zhang, S.J. Yue, H.L. Sun*, R. Haag, Z.Y. Zhong*, An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer, J. Control. Release. 2021, 340, 331-341.

9. Z. Wang, F.H. Meng, and Z.Y. Zhong*, Emerging targeted drug delivery strategies toward ovarian cancer, Adv. Drug Deliv. Rev. 2021, 178, 113969

10. N. Yu, Y.F. Zhang, J.Y. Li, W.X. Gu, S.J. Yue, B. Li, F.H. Meng, H.L. Sun*, R. Haag, J.D. Yuan, andZ.Y. Zhong*, Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma, Adv. Mater. 2021, 33, 2007787.

11. Y.H. Wei, Y.P. Sun, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo, J. Control. Release. 2021, 337, 521-529.

12. W.X. Gu, R.B. Qu, F.H. Meng*,J.L.M. Cornelissen*, andZ.Y. Zhong*,Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release. 2021, 337, 571-588.

13. Y.F. Xia, J.J. Wei, S.S. Zhao, B.B. Guo, F.H. Meng*, B. Klumperman, andZ.Y. Zhong*,Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Control. Release. 2021, 336, 262-273.

14. Z.Y. Zhong*, Controlled delivery systems are the cornerstone of advanced therapies and vaccines: An Asian perspective, J. Control. Release. 2021, 334, 34-36.

15. Q.Y. Fan, Y.Y. Liu, G.H. Cui, Z.Y. Zhong*,andC. Deng*, Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma, J. Control. Release. 2021, 329, 1139-1149.

16. W.X. Gu, T.H. Liu, D.Y. Fan, J.B. Zhang, Y.F. Xia, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, Z.J. Liu, andZ.Y. Zhong*,A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia, J. Control. Release. 2021, 329, 706-716.

17. W.X. Gu, F.H. Meng*, R. Haag, andZ.Y. Zhong*,Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation, J. Control. Release. 2021, 329, 676-695.

18. C. Gao, Q. Cheng, J.W. Wei, C. Sun, S.Y. Lu, C.H.T. Kwong, S.M.Y. Lee, Z.Y. Zhong*, and R.B. Wang*, Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery, Mater. Today. 2020, 40, 9-17.

19. C. Deng*, Q. Zhang, J.Q. Guo, X.F. Zhao, and Z.Y. Zhong*, Robust and smart polypeptide-based nanomedicines for targeted tumor therapy, Adv. Drug Deliv. Rev. 2020, 160, 199-211.

20. H.L. Sun, and Z.Y. Zhong*, 100th Anniversary of Macromolecular Science Viewpoint: Biological Stimuli-Sensitive Polymer Prodrugs and Nanoparticles for Tumor-Specific Drug Delivery, ACS Macro Lett. 2020, 9, 1292-1302.

21. Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release. 2020, 319, 407-415.

22. Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, andZ.Y. Zhong*,CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release. 2020, 320, 421-430.

23. X.L. Gu, Z.H. Zhu, Y.H. Wei, G.L. Wang, F.H. Meng, Z.Y. Zhong*, and C. Deng*, Nano-Agents Based on Poly(ethylene glycol)-b-Poly(L-thyroxine) Block Copolypeptide for Enhanced Dual-Modality Imaging and Targeted Tumor Radiotherapy, Small. 2019, 15, 1902577.

24. Y. Zou, Y.H. Wei, J. Bao, F.R. Yao, Z.K. Li, Y.P. Sun, F.H. Meng*, C.H. Hu, G. Storm, andZ.Y. Zhong*, Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Melanoma, Theranostics. 2019, 9, 8061-8072.

25. W.X. Gu, J.N. An, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, andZ.Y. Zhong*,CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater.2019, 1904742.

26. H.Z. Qin, Y. Jiang, J. Zhang, C. Deng*, and Z.Y. Zhong*, Oncoprotein Inhibitor Rigosertib Loaded in ApoE-Targeted Smart Polymersomes Reveals a High Safety and Potency against Human Glioblastoma in Mice, Mol. Pharmaceutics. 2019, 16, 3711-3719.

27. M. Qiu, J. Ouyang, Y.H. Wei, J. Zhang, Q. Lan, C. Deng*, and Z.Y. Zhong*, Selective cell penetrating peptide-functionalized envelope-type chimaeric lipopepsomes boost systemic RNAi therapy for lung tumor, Adv. Healthcare Mater. 2019, 1900500.

28. X.L. Gu, Y.H. Wei, Q.Y. Fan, H.L. Sun, R. Cheng, Z.Y. Zhong*, and C. Deng*, cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo, J. Control. Release. 2019, 301, 110-118.

29. W.X. Gu, J.N. An, H. Meng, N. Yu, Y.N. Zhong, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, and Z.Y. Zhong*, CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma, Adv. Mater. 2019, 1904742.

30. Y. Jiang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*, Apolipoprotein E Peptide-Directed Chimeric Polymersomes Mediate an Ultrahigh-Efficiency Targeted Protein Therapy for Glioblastoma, ACS Nano. 2018, 12, 11070-11079.

31. Y. Jiang, W.J. Yang, J. Zhang*, F.H. Meng, and Z.Y. Zhong*, Protein Toxin Chaperoned by LRP-1 Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo, Adv. Mater. 2018, 30, 1800316.

32. Y.Q. Zhu, J. Feijen*, and Z.Y. Zhong*, Dual-Targeted Nanomedicines for Enhanced Tumor Treatment, Nano Today. 2018, 18, 65-85.

33. Y. Zou, M. Zheng, W.J. Yang, F.H. Meng*, K. Miyata, H.J. Kim, K. Kataoka*, and Z.Y. Zhong*, Virus-Mimicking Chimaeric Polymersome Boosts Targeted Cancer siRNA Therapy in Vivo, Adv. Mater. 2017, 29, 1703285